Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Tetrahydrofuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1045488 | 0.86 | PNMT (0.41) | P2RX7AKR1B1PNMT | |
| Hydrochloric Acid SCHEMBL4204405 | 0.82 | PNMT (0.41) | P2RX7AKR1B1PNMT | |
| Iodide SCHEMBL28056490 | 0.82 | PNMT (0.41) | P2RX7AKR1B1PNMT | |
| Tetrahydrofuran SCHEMBL21814336 | 0.81 | CYP2A13 (0.40) | CYP2A13OPRL1MGLLKDM4EP2RX7 | |
| Tetrahydrofuran SCHEMBL28435126 | 0.79 | CYP2A13 (0.49) | CYP2A13OPRL1KDM4EAKR1B1ALDH1A1 | |
| SCHEMBL148553 | 0.70 | PNMT (0.41) | CYP2A13P2RX7AKR1B1PNMT | |
| Tetrahydrofuran SCHEMBL21177351 | 0.69 | CYP2A13 (0.48) | CYP2A13KDM4EALDH1A1POLBPNMT | |
| Tetrahydrofuran SCHEMBL9684561 | 0.69 | CYP2A13 (0.53) | CYP2A13MGLLKDM4EKCNH2ALDH1A1 | |
| 1,2-Dichlorobenzene SCHEMBL4473756 | 0.69 | LMNA (0.56) | CYP2A13MGLLALDH1A1 | |
| SCHEMBL3069271 | 0.68 | PNMT (0.43) | P2RX7AKR1B1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | disclosed |
| EP-3287130-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND PROTEASE INHIBITORS | Japan Tobacco Inc. (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140364389-A1 | Combination Therapy | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8633219-B2 | Combination therapy | JAPAN TOBACCO INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. | 2013-07-04 | — | — | US | disclosed |
| US-8232401-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2332538-A1 | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents | Japan Tobacco, Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
| EP-2161258-A2 | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor | Japan Tabacco Inc. (JP) | 2010-03-10 | — | — | EP | disclosed |
| EP-1564210-B1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-1758581-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | Japan Tobacco, Inc. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20050288326-A1 | Combination therapy | SHIONOGI & CO., LTD. (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005112930-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288326-A1 | Combination therapy | TYMP, TPMT, PNP | CYP2A13 279/4885OPRL1 1146/4885MGLL 2019/4885 |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | CYP2A13 680/4885OPRL1 3863/4885MGLL 2204/4885 |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | CYP2A13 1620/4885OPRL1 2670/4885MGLL 3008/4885 |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | CYP2A13 1620/4885OPRL1 2670/4885MGLL 3008/4885 |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, CDKL4, IMPDH2 | CYP2A13 2166/4885OPRL1 3132/4885MGLL 3139/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | CYP2A13 2101/4885OPRL1 2420/4885MGLL 3151/4885 |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, CDKL4, IMPDH2 | CYP2A13 2166/4885OPRL1 3132/4885MGLL 3139/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | CYP2A13 1988/4885OPRL1 3039/4885MGLL 3114/4885 |
| US-20140364389-A1 | Combination Therapy | TYMP, TPMT, PNP | CYP2A13 279/4885OPRL1 1146/4885MGLL 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.